The study investigates the increased neurogenesis in the hippocampus of patients with Alzheimer's disease (AD). Using immunohistochemistry and Western blotting, researchers found that the expression of several neurogenesis marker proteins, such as doublecortin (DCX), polysialylated nerve cell adhesion molecule (PSA-NCAM), TUC-4, and neurogenic differentiation factor (NeuroD), was significantly higher in the hippocampus of AD patients compared to controls. These markers were localized to the neuroproliferative zone (SGZ) and the CA1 region, which are key sites of hippocampal pathology in AD. The findings suggest that increased neurogenesis in the AD hippocampus may contribute to the replacement of lost neurons and could potentially be a therapeutic strategy for AD. The study also highlights the potential role of growth factors and environmental enrichment in enhancing neurogenesis, which could have significant implications for the treatment of AD.The study investigates the increased neurogenesis in the hippocampus of patients with Alzheimer's disease (AD). Using immunohistochemistry and Western blotting, researchers found that the expression of several neurogenesis marker proteins, such as doublecortin (DCX), polysialylated nerve cell adhesion molecule (PSA-NCAM), TUC-4, and neurogenic differentiation factor (NeuroD), was significantly higher in the hippocampus of AD patients compared to controls. These markers were localized to the neuroproliferative zone (SGZ) and the CA1 region, which are key sites of hippocampal pathology in AD. The findings suggest that increased neurogenesis in the AD hippocampus may contribute to the replacement of lost neurons and could potentially be a therapeutic strategy for AD. The study also highlights the potential role of growth factors and environmental enrichment in enhancing neurogenesis, which could have significant implications for the treatment of AD.